Drug Trial Radar · NCT00738101
Compassionate Use of an Intravenous Fish Oil Emulsion in the Treatment of Liver Injury in Infants
Last checked: Nov 20, 2026Latest source record: May 28, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
293
Actual
Start
Sep 2008
Primary completion
Mar 27, 2019
Study completion Mar 27, 2020
Sponsor
- Lead sponsor
- Baylor College of MedicineAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Boston Children's Hospital
- First posted
- Aug 20, 2008
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 14 days, up to 5 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To provide a mechanism for critically ill infants with parenteral nutrition (PN) associated cholestasis to receive Omegaven for compassionate use situations for which there are no satisfactory alternative treatments.
Conditions
- Cholestasis
- Cholestasis of Parenteral Nutrition
Interventions
OmegavenDrug
Therapy with Omegaven will be provided at a dose of 1 gm/kg/day (by continuous infusion). Omegaven will be infused intravenously through either a central or peripheral catheter in conjunction with parenteral nutrition. Treatment will be given for as long as the child needs any TPN AND has a conjugated bilirubin greater than 2 mg/dL for a maximum of 5 years. If the infant no longer is requiring any TPN, then the Omegaven will be stopped regardless of bilirubin. If the bilirubin is less than 2 mg/dL but the child still requires TPN, then the Omegaven will be continued until the infant no longer requires TPN.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to Resolution of Parenteral Nutrition Associated Cholestasis Prior to End of StudyTime frame: From initiation to end of study (End of Study : Discontinuation of Fish Oil Emulsion, Death, Transplant, or Discharge from the hospital, whichever is achieved first, up to 5 years).
- All Cause Mortality During the Study.Time frame: From initiation to end of study (End of Study : Discontinuation of Fish Oil Emulsion, Death, Transplant, or Discharge from the hospital, whichever is achieved first, up to 5 years).
- Growth Z-scores for WeightTime frame: From initiation to end of study (End of Study : Discontinuation of Fish Oil Emulsion, Death, Transplant, or Discharge from the hospital, whichever is achieved first, up to 5 years).
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Baylor College of Medicine
Houston, Texas
Texas Children's Hospital
Houston, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.